Replies to post #19564 on Biotech Values

[DewDiligence]

BOL had a second ophthalmology deal announced today that was all but ignored amid the attention devoted to the deal with CEPH:

http://biz.yahoo.com/bw/051201/20051201005411.html?.v=1

>>
Bausch & Lomb and PTC Therapeutics Announce Anti-Angiogenesis Collaboration in Ophthalmology

ROCHESTER, N.Y. & SOUTH PLAINFIELD, N.J.--(BUSINESS WIRE)--Dec. 1, 2005--Bausch & Lomb (NYSE: BOL ) and PTC Therapeutics, Inc., a privately held biopharmaceutical company, today announced an exclusive option agreement for Bausch & Lomb to license selected PTC compounds as development candidates for therapeutic use in ophthalmology.

PTC's anti-angiogenesis program was developed through PTC's proprietary GEMS technology - Gene Expression Modulation by Small Molecules. "Our research collaboration with PTC Therapeutics provides Bausch & Lomb with access to a broad range of compounds from PTC's anti-angiogenesis program that are potential candidates for development," said Praveen Tyle, Ph.D., Bausch & Lomb Chief Scientific Officer and senior vice president - Global Research & Development. "PTC has identified a number of promising small-molecule compounds that show anti-angiogenic activity, that is, compounds that demonstrate high potency for blocking the abnormal growth of blood vessels. The goal of our collaboration is to apply our research expertise to develop these compounds as unique therapies for diseases of ocular neovascularization including macular degeneration."

"Our collaboration with Bausch & Lomb is well-aligned with our strategy of efficiently expanding the use of our compounds with partners that have outstanding expertise in specific therapeutic areas," stated Stuart Peltz, Ph.D., president and CEO of PTC Therapeutics. "We are delighted to be collaborating with Bausch & Lomb and look forward to the opportunity to identify new therapies to treat ophthalmologic diseases."

Financial details of the agreement were not disclosed.
<<